Filing Flows › EyePoint (EYPT) › Q1 2026 › vs Q1 2025
EyePoint (EYPT) Q1 2026 vs Q1 2025 (year over year)
EyePoint's revenue fell $23.8M (-97%) from $24.5M in Q1 2025 to $696K in Q1 2026. The biggest changes: Royalty −$12.5M (-99%); License and Collaboration Agreement −$11.0M (-99%); Product −$248K (-35%).
EyePoint, Q1 2026: revenue $696K (-97% year over year), net loss $84.8M, operating cash flow −$80.5M. The chart draws each line against Q1 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q1 2025 | Change | % |
|---|---|---|---|---|
| Product | $467K | $715K | −$248K | -35% |
| Royalty | $141K | $12.7M | −$12.5M | -99% |
| License and Collaboration Agreement | $88K | $11.0M | −$11.0M | -99% |
| Revenue | $696K | $24.5M | −$23.8M | -97% |
| Other income, net | $2.3M | $3.6M | −$1.3M | -36% |
| Income tax benefit | $50K | $0 | $50K | — |
| Net loss | $84.8M | $45.2M | $39.6M | +88% |
| Costs & expenses | $87.9M | $73.3M | $14.6M | +20% |
| Operating costs | $87.9M | $73.3M | $14.6M | +20% |
| Research & development | $72.1M | $58.6M | $13.6M | +23% |
| Sales & marketing | $3K | $35K | −$32K | -91% |
| General & admin | $15.2M | $13.9M | $1.4M | +10% |
| Other operating costs | $528K | $805K | −$277K | -34% |
| Operating cash sources | $92.8M | $61.4M | $31.4M | +51% |
| Depreciation & amortization | $636K | $497K | $139K | +28% |
| Share-based compensation | $11.6M | $7.8M | $3.8M | +49% |
| Cash used in operations | $80.5M | $53.1M | $27.4M | +52% |
| Net loss absorbed | $84.8M | $45.2M | $39.6M | +88% |
| Working capital & other | $8.0M | $16.2M | −$8.3M | -51% |
Questions
How much did EyePoint's revenue grow year over year in Q1 2026?
EyePoint's revenue fell $23.8M (-97%) from $24.5M in Q1 2025 to $696K in Q1 2026.
What drove EyePoint's revenue change in Q1 2026?
Royalty −$12.5M (-99%); License and Collaboration Agreement −$11.0M (-99%); Product −$248K (-35%).